BALA CYNWYD, Pa., May 29, 2013 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Omthera Pharmaceuticals, Inc. ("Omthera" or the "Company") (Nasdaq: OMTH) relating to the proposed acquisition by AstraZeneca PLC.

Click here to learn more about the investigation http://brodsky-smith.com/595-omth-omthera-pharmaceuticals-inc.html, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Omthera shareholders will receive only $12.70 in cash for each share of Omthera stock they own. In addition, Omthera shareholders will receive approximately $4.70 in contingent value rights if certain benchmarks are met. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Omthera for not acting in the Company's shareholders' best interests in connection with the sale process. The transaction may undervalue the Company as Omthera expects to seek a new drug approval for Epanova, a treatment for cardiovascular disease, from the FDA in mid-2013.  

If you own shares of Omthera common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, by visiting http://brodsky-smith.com/595-omth-omthera-pharmaceuticals-inc.html, or calling toll free 877-LEGAL-90. 
 
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome. 

SOURCE Brodsky & Smith, LLC

Copyright 2013 PR Newswire

OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos OMTHERA PHARMACEUTICALS, INC..
OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos OMTHERA PHARMACEUTICALS, INC..